Cargando…

The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial

INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical appl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mo, Lyu, Ji-hui, Zhang, Yi, Gao, Mao-long, Li, Wen-jie, Ma, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758240/
https://www.ncbi.nlm.nih.gov/pubmed/29390538
http://dx.doi.org/10.1097/MD.0000000000009381
_version_ 1783290972536307712
author Li, Mo
Lyu, Ji-hui
Zhang, Yi
Gao, Mao-long
Li, Wen-jie
Ma, Xin
author_facet Li, Mo
Lyu, Ji-hui
Zhang, Yi
Gao, Mao-long
Li, Wen-jie
Ma, Xin
author_sort Li, Mo
collection PubMed
description INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical application in China; the evidence-based efficacy of reminiscence therapy in AD patients remains to be determined. Therefore, the aim of this research is to assess the effectives of reminiscence therapy for Chinese elderly. METHODS AND ANALYSIS: This is a randomized parallel-design controlled trial. Mild and moderate AD patients who are in the Beijing Geriatric Hospital, China will be randomized into control and intervention groups (n = 45 for each group). For the intervention group, along with conventional drug therapy, participants will be exposed to a reminiscence therapy of 35 to 45 minutes, 2 times/wk for 12 consecutive weeks. Patients in the control group will undergo conventional drug therapy only. The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score. The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment. ETHICS AND DISSEMINATION: The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010). Findings will be disseminated through presentation at scientific conferences and in academic journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505.
format Online
Article
Text
id pubmed-5758240
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57582402018-01-29 The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial Li, Mo Lyu, Ji-hui Zhang, Yi Gao, Mao-long Li, Wen-jie Ma, Xin Medicine (Baltimore) 4600 INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical application in China; the evidence-based efficacy of reminiscence therapy in AD patients remains to be determined. Therefore, the aim of this research is to assess the effectives of reminiscence therapy for Chinese elderly. METHODS AND ANALYSIS: This is a randomized parallel-design controlled trial. Mild and moderate AD patients who are in the Beijing Geriatric Hospital, China will be randomized into control and intervention groups (n = 45 for each group). For the intervention group, along with conventional drug therapy, participants will be exposed to a reminiscence therapy of 35 to 45 minutes, 2 times/wk for 12 consecutive weeks. Patients in the control group will undergo conventional drug therapy only. The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score. The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment. ETHICS AND DISSEMINATION: The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010). Findings will be disseminated through presentation at scientific conferences and in academic journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505. Wolters Kluwer Health 2017-12-22 /pmc/articles/PMC5758240/ /pubmed/29390538 http://dx.doi.org/10.1097/MD.0000000000009381 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4600
Li, Mo
Lyu, Ji-hui
Zhang, Yi
Gao, Mao-long
Li, Wen-jie
Ma, Xin
The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
title The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
title_full The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
title_fullStr The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
title_full_unstemmed The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
title_short The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
title_sort clinical efficacy of reminiscence therapy in patients with mild-to-moderate alzheimer disease: study protocol for a randomized parallel-design controlled trial
topic 4600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758240/
https://www.ncbi.nlm.nih.gov/pubmed/29390538
http://dx.doi.org/10.1097/MD.0000000000009381
work_keys_str_mv AT limo theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT lyujihui theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT zhangyi theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT gaomaolong theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT liwenjie theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT maxin theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT limo clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT lyujihui clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT zhangyi clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT gaomaolong clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT liwenjie clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial
AT maxin clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial